➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Dow
Boehringer Ingelheim
McKesson
Colorcon

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Docket   Start Trial Date Filed 2018-02-01
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Defendant Referred To Christopher J. Burke
Parties CADILA HEALTHCARE LIMITED
Patents 10,004,746; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 7,514,444; 8,008,309; 8,476,284; 8,497,277; 8,697,711; 8,735,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883
Attorneys Mark T. Deming
Firms Heyman Enerio Gattuso & Hirzel LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Pharmacyclics LLC v. Cipla Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Pharmacyclics LLC v. Cipla Limited

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Pharmacyclics LLC v. Cipla Limited (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-02-01 1 United States Patent Nos. 8,008,309 (“the ’309 Patent”); 7,514,444 (“the ’444 Patent”); 8,697,711 (“…(“the ’711 Patent”); 8,735,403 (“the ’403 Patent”); 8,957,079 (“the ’079 Patent”); 9,181,257 (“the ’257…’257 Patent”); 8,754,091 (“the ’091 Patent”); 8,497,277 (“the ’277 Patent”); 8,952,015 (“the ’015 Patent…37 PageID #: 2 Patent”); 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 (“the… 1. This action for patent infringement, brought pursuant to the patent laws of the United States External link to document
2019-02-14 103 ’548 Patents, and U.S. Patent Nos. 8,999,999 (“the ’999 Patent”); 9,801,881 (“the ’881 Patent”); 9,801,883… 16304 Patent”); 10,125,140 (“the ’140 Patent”); and 10,106,548 (“the ’548 Patent”). Sun has submitted… 1. This action for patent infringement, brought pursuant to the patent laws of the United States… the expiration of the U.S. Patent Nos. 9,296,753 (“the ’753 Patent”) 9,725,455 (“the ’455 Case 1:18…26. This civil action for patent infringement arises under the patent laws of the United States External link to document
2019-02-14 104 B2 ;9,801,881 B2 ;9,801,883 B2 ;10,125,140 B1 ;10,106,548 B2. (fms) (Entered: 02/14/2019) 14 February… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,296,753 B2 ;… 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2019-03-15 128 Answer to Counterclaim Admitted. 17. U.S. Patent No. 10,106,548 (“the ’548 Patent”), on its face, is titled “Crystalline…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…’753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the…753 Patent, the ’455 Patent, the ’382 Patent, the ’617 Patent, the ’090 Patent, the ’889 Patent, the External link to document
2019-05-24 161 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,016,435 B2 . (Blumenfeld, … 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
2019-05-29 163 Complaint - Amended ’889 Patent”); 10,125,140 (“the ’140 Patent”); 10,106,548 (“the ’548 Patent”); and 10,016,435 (“the…expiration of U.S. Patent Nos. 9,296,753 (“the ’753 Patent”); 9,725,455 (“the ’455 Patent”); 9,540,382 … (“the ’382 Patent”); 9,713,617 (“the ’617 Patent”); 8,754,090 (“the ’090 Patent”); 9,125,889 Case 1:… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…23. This civil action for patent infringement arises under the patent laws of the United States, External link to document
2019-08-01 199 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,294,232 . (Blumenfeld, Jack… 1 February 2018 1:18-cv-00192 835 Patent - Abbreviated New Drug Application(ANDA) Defendant External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Harvard Business School
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.